Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Breast: MetastaticNCT ID: NCT01670877
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-237
This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
Conducting Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital
Overall PI: Rachel Freedman, MD,
Dana Farber Cancer Institute
Contacts: Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478